title: High serum levels of soluble Fas (sFas) in CKD patients: effects of renal clearance, reabsorption and synthesis.
abstract: OBJECTIVE
  Increased serum concentrations of soluble Fas (sFas) have been reported in patients with chronic kidney disease (CKD). However, little is known about the renal clearance of sFas, whether sFas is reabsorbed in the renal tubules, or the behavior of sFas synthesis in CKD.
  
  
  METHODS
  We studied 69 patients with CKD (60+/-15 years old, creatinine clearance 37+19 ml/min/1.73 m2) and 14 healthy subjects (61+/-17 years, creatinine clearance 79+/-24 ml/min/1.73 m2). ELISA was used to measure the levels of sFas (pg/mL) and retinol binding protein (RBP - mg/L). RT-PCR was used to quantify sFasmRNA of leukocytes.
  
  
  RESULTS
  Serum sFas levels were significantly higher in patients with CKD (2781+/-1214 vs. 2196+/-773, p=0.02). The concentrations of sFas in 24-hour urine samples (23+/-27 vs. 40+/-17, p=0.006) and sFas Clearance (0.019+/-0.022 vs. 0.036+/-0.020, p=0.01) were significantly lower in patients with CKD. sFas clearance correlated with creatinine clearance (r=0.25, p=0.02). Urine concentrations of RBP correlated with sFas concentrations in the urine (r=0.80, p<0.001). sFasmRNA were higher in patients with CKD (3.9+/-1.8 vs. 2.5+/-0.9, p<0.001).
  
  
  CONCLUSIONS
  In CKD patients, the decrease in renal function is followed by a decrease in sFas clearance and an increase in serum sFas. In patients with proximal tubule dysfunction (high urinary RBP concentrations), urinary sFas is also increased, suggesting that sFas is reabsorbed by the proximal tubule. It is possible that an increase in sFas synthesis also contributes to the increase of serum sFas concentrations in uremia.
authors.affiliation: Division of Nephrology, Department of Medicine, Federal University of San Paulo, San Paulo - Brazil. dalboni@nefro.epm.br
authors.forename: M A
authors.initials: MA
authors.lastname: Dalboni
authors.forename: M A
authors.initials: MA
authors.lastname: Cenedeze
authors.forename: S R
authors.initials: SR
authors.lastname: Manfredi
authors.forename: M C
authors.initials: MC
authors.lastname: Cruz Andreoli
authors.forename: O
authors.initials: O
authors.lastname: Pavao Dos Santos
authors.forename: M E
authors.initials: ME
authors.lastname: Canziani
authors.forename: M A
authors.initials: MA
authors.lastname: Boim
authors.forename: M A
authors.initials: MA
authors.lastname: Goes
authors.forename: S A
authors.initials: SA
authors.lastname: Draibe
authors.forename: V
authors.initials: V
authors.lastname: Balakrishnan
authors.forename: M
authors.initials: M
authors.lastname: Cendoroglo
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000378:metabolism*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D012177:Retinol-Binding Proteins / Q000378:metabolism / Q000652:urine; D019014:fas Receptor / Q000097:blood / Q000378:metabolism*
chemical_list: C491901:FAS protein, human; D012177:Retinol-Binding Proteins; D019014:fas Receptor